Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit.
hepatopancreaticobiliary surgery
outcomes
pancreas
pancreas cancer
surgical oncology
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
05
05
2023
received:
19
03
2023
accepted:
08
05
2023
medline:
29
11
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
ppublish
Résumé
The Victorian Government convened the second Pancreas Cancer Summit in 2021 to identify unwarranted variation in care 2016-2019, and to assess trends compared with the first Summit 2017 (reporting 2011-2015). State-wide administrative data were assessed at population level in alignment with optimal care pathways across all stages of the cancer care continuum. Data linkage performed by Centre for Victorian Data Linkage combined data from Victorian Cancer Registry with other administrative data sets including Victorian Admitted Episodes Dataset, Victorian Radiotherapy Minimum Data Set, Victorian Emergency Minimum Dataset and Victorian Death Index. A Cancer Service Performance Indicator audit was carried out providing an in-depth analysis of identified areas of interest. Of 3138 Victorians diagnosed with pancreas ductal adenocarcinoma 2016-2019, 63% were metastatic at diagnosis. One-year survival increased between time periods, from 29.7% overall 2011-2015 (59.1% for non-metastatic, and 15.1% metastatic) to 32.5% overall 2016-2019 (P < 0.001), 61.2% non-metastatic (P = 0.008), 15.7% metastatic (P = NS). A higher proportion of non-metastatic patients progressed to surgery (35% vs. 31%, P = 0.020), and more received neoadjuvant therapy (16% vs. 4%, P < 0.001). Postoperative mortality following pancreatectomy at 30 and 90 days remained low at 2%. Utilization of 5FU-based chemotherapy regimens increased between 2016 and 2020. Multidisciplinary Meeting (MDM) presentation was still below the 85% target (74%) as was supportive care screening (39%, target 80%). Surgical outcomes remain world-class and there has been an appropriate shift in chemotherapy administration towards neoadjuvant timing with increasing use of 5FU-based regimens. MDM presentation rates, supportive care and overall care coordination remain areas of deficiency.
Sections du résumé
BACKGROUND
The Victorian Government convened the second Pancreas Cancer Summit in 2021 to identify unwarranted variation in care 2016-2019, and to assess trends compared with the first Summit 2017 (reporting 2011-2015). State-wide administrative data were assessed at population level in alignment with optimal care pathways across all stages of the cancer care continuum.
METHODS
Data linkage performed by Centre for Victorian Data Linkage combined data from Victorian Cancer Registry with other administrative data sets including Victorian Admitted Episodes Dataset, Victorian Radiotherapy Minimum Data Set, Victorian Emergency Minimum Dataset and Victorian Death Index. A Cancer Service Performance Indicator audit was carried out providing an in-depth analysis of identified areas of interest.
RESULTS
Of 3138 Victorians diagnosed with pancreas ductal adenocarcinoma 2016-2019, 63% were metastatic at diagnosis. One-year survival increased between time periods, from 29.7% overall 2011-2015 (59.1% for non-metastatic, and 15.1% metastatic) to 32.5% overall 2016-2019 (P < 0.001), 61.2% non-metastatic (P = 0.008), 15.7% metastatic (P = NS). A higher proportion of non-metastatic patients progressed to surgery (35% vs. 31%, P = 0.020), and more received neoadjuvant therapy (16% vs. 4%, P < 0.001). Postoperative mortality following pancreatectomy at 30 and 90 days remained low at 2%. Utilization of 5FU-based chemotherapy regimens increased between 2016 and 2020. Multidisciplinary Meeting (MDM) presentation was still below the 85% target (74%) as was supportive care screening (39%, target 80%).
CONCLUSIONS
Surgical outcomes remain world-class and there has been an appropriate shift in chemotherapy administration towards neoadjuvant timing with increasing use of 5FU-based regimens. MDM presentation rates, supportive care and overall care coordination remain areas of deficiency.
Substances chimiques
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2638-2647Informations de copyright
© 2023 The Authors. ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.
Références
Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for people with pancreatic cancer, 2nd edn. Melbourne: Cancer Council Victoria, 2021.
Pilgrim CHC, te Marvelde L, Stuart E et al. Population-based analysis of treatment patterns and outcomes for pancreas cancer in Victoria. ANZ J. Surg. 2020; 90: 1677-82.
Quan H, Li B, Couris CM et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 2011; 173: 676-82.
NCCN Guidelines(R). Updates. J. Natl. Compr. Cancer Netw. 2013; 11: xxxiv-vi.
Versteijne E, Suker M, Groothuis K et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J. Clin. Oncol. 2020; 38: 1763-73.
Katz MH, Pisters PWT, Evans DB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J. Am. Coll. Surg. 2008; 206: 833-46 discussion 846-8.
Isaji S, Mizuno S, Windsor JA et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018; 18: 2-11.
Pilgrim CHC, Maciejewska A, Ayres N et al. Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot. ANZ J. Surg. 2022; 92: 2565-70.
Davis MP, Temel JS, Balboni T, Glare P. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med 2015; 4: 99-121.
Fulton JJ, LeBlanc TW, Cutson TM et al. Integrated outpatient palliative care for patients with advanced cancer: a systematic review and meta-analysis. Palliat. Med. 2019; 33: 123-34.
Gaertner J, Siemens W, Meerpohl JJ et al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis. BMJ 2017; 357: j2925.
Haun MW, Estel S, Rücker G et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst. Rev. 2017; 6: CD011129.
Hoerger M, Wayser GR, Schwing G, Suzuki A, Perry LM. Impact of interdisciplinary outpatient specialty palliative care on survival and quality of life in adults with advanced cancer: a meta-analysis of randomized controlled trials. Ann. Behav. Med. 2019; 53: 674-85.
Kavalieratos D, Corbelli J, Zhang D et al. Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. JAMA 2016; 316: 2104-14.
Philip J, Collins A, Warwyk O, Sundararajan V, le B. Is the use of palliative care services increasing? A comparison of current versus historical palliative care access using health service datasets for patients with cancer. Palliat. Med. 2022; 36: 1426-31.
Collins A, McLachlan SA, Philip J. Initial perceptions of palliative care: an exploratory qualitative study of patients with advanced cancer and their family caregivers. Palliat. Med. 2017; 31: 825-32.
Le BH, Mileshkin L, Doan K et al. Acceptability of early integration of palliative care in patients with incurable lung cancer. J. Palliat. Med. 2014; 17: 553-8.
Philip J, le Gautier R, Collins A et al. Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol. BMC Health Serv. Res. 2021; 21: 513.
Beesley VL, Janda M, Goldstein D et al. A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services. Psychooncology 2016; 25: 150-7.
Khan NN, Maharaj A, Evans S et al. A qualitative investigation of the supportive care experiences of people living with pancreatic and oesophagogastric cancer. BMC Health Serv. Res. 2022; 22: 213.
Khan NN, Basrai H, Evans SM et al. Landscape of clinical trials across the pancreatic cancer care continuum: an Australian perspective. Med. J. Aust. 2022; 217: 505-9.